These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22618469)

  • 1. Individualization of a pharmacokinetic model by fractional and nonlinear fit improvement.
    Popović JK; Poša M; Popović KJ; Popović DJ; Milošević N; Tepavčević V
    Eur J Drug Metab Pharmacokinet; 2013 Mar; 38(1):69-76. PubMed ID: 22618469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nonlinear two compartmental fractional derivative model.
    Popović JK; Dolićanin D; Rapaić MR; Popović SL; Pilipović S; Atanacković TM
    Eur J Drug Metab Pharmacokinet; 2011 Dec; 36(4):189-96. PubMed ID: 21805207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new approach to the compartmental analysis in pharmacokinetics: fractional time evolution of diclofenac.
    Popović JK; Atanacković MT; Pilipović AS; Rapaić MR; Pilipović S; Atanacković TM
    J Pharmacokinet Pharmacodyn; 2010 Apr; 37(2):119-34. PubMed ID: 20072802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of bumetanide in the newborn infant.
    Lopez-Samblas AM; Adams JA; Goldberg RN; Modi MW
    Biol Neonate; 1997; 72(5):265-72. PubMed ID: 9395836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of a physiologically-based pharmacokinetic model for the prediction of bumetanide plasma and brain concentrations in the neonate.
    Donovan MD; Abduljalil K; Cryan JF; Boylan GB; Griffin BT
    Biopharm Drug Dispos; 2018 Mar; 39(3):125-134. PubMed ID: 29319897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and diuretic effect after administration of retarded capsules of bumetanide in human subjects.
    Yagi N; Kiuchi T; Satoh H; Ishikawa Y; Takada M; Sekikawa H
    Biol Pharm Bull; 1999 Mar; 22(3):275-80. PubMed ID: 10220284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal administration of different liquid formulations of bumetanide to rabbits.
    Nielsen HW; Bechgaard E; Twile B; Didriksen E; Sørensen H
    Int J Pharm; 2000 Aug; 204(1-2):35-41. PubMed ID: 11011983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fractional kinetics in multi-compartmental systems.
    Dokoumetzidis A; Magin R; Macheras P
    J Pharmacokinet Pharmacodyn; 2010 Oct; 37(5):507-24. PubMed ID: 20886267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two compartmental fractional derivative model with general fractional derivative.
    Miskovic-Stankovic V; Janev M; Atanackovic TM
    J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):79-87. PubMed ID: 36478532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of the pharmacodynamic differences between immediate and extended release bumetanide formulations.
    Hamed E; Gerson MC; Millard RW; Sakr A
    Int J Pharm; 2003 Nov; 267(1-2):129-40. PubMed ID: 14602391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of bumetanide in critically ill pediatric patients.
    Marshall JD; Wells TG; Letzig L; Kearns GL
    J Clin Pharmacol; 1998 Nov; 38(11):994-1002. PubMed ID: 9824779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure.
    Cook JA; Smith DE; Cornish LA; Tankanow RM; Nicklas JM; Hyneck ML
    Clin Pharmacol Ther; 1988 Nov; 44(5):487-500. PubMed ID: 3180632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects.
    Holazo AA; Colburn WA; Gustafson JH; Young RL; Parsonnet M
    J Pharm Sci; 1984 Aug; 73(8):1108-13. PubMed ID: 6491914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical identifiability and convergence evaluation for nonlinear pharmacokinetic models with particle swarm optimization.
    Kim S; Li L
    Comput Methods Programs Biomed; 2014 Feb; 113(2):413-32. PubMed ID: 24216078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects.
    Kim EJ; Lee MG
    Biopharm Drug Dispos; 2001 May; 22(4):147-56. PubMed ID: 11745917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of bumetanide in critically ill infants.
    Sullivan JE; Witte MK; Yamashita TS; Myers CM; Blumer JL
    Clin Pharmacol Ther; 1996 Oct; 60(4):405-13. PubMed ID: 8873688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of non-linear mixed effects models defined by fractional differential equations.
    Kaikousidis C; Dokoumetzidis A
    J Pharmacokinet Pharmacodyn; 2023 Aug; 50(4):283-295. PubMed ID: 36944853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterial and venous blood sampling in pharmacokinetic studies: bumetanide in rabbits.
    Chung SY; Yoon WH; Kim SH; Hwang KS; Lee MG
    Res Commun Mol Pathol Pharmacol; 1997 Dec; 98(3):255-64. PubMed ID: 9485520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of parameters in the linear-fractional models.
    Wu FX
    Annu Int Conf IEEE Eng Med Biol Soc; 2007; 2007():1086-9. PubMed ID: 18002150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of bumetanide in human plasma for a bioequivalence study.
    Patel DS; Sharma N; Patel MC; Patel BN; Shrivastav PS; Sanyal M
    J Pharm Biomed Anal; 2012 Jul; 66():365-70. PubMed ID: 22475517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.